WASHINGTON, May 20, 2020 /PRNewswire/ -- Vanda
Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that
the Federal District Court in Washington
D.C. granted Vanda's motion to dismiss a False Claims Act
lawsuit filed against the company.
On May 19, 2020, Judge
Amit P. Mehta granted Vanda's motion
to dismiss the lawsuit, concluding that the relator's allegations
fail to state a viable claim under the False Claims Act. At the
relator's request, the Court will allow an amended complaint in
which the relator may attempt to remedy pleading deficiencies. If
the relator does replead, Vanda anticipates filing a renewed motion
to dismiss.
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on
the development and commercialization of innovative therapies to
address high unmet medical needs and improve the lives of patients.
For more on Vanda Pharmaceuticals Inc., please visit
www.vandapharma.com and follow us on Vanda's Twitter and
LinkedIn.
About the False Claims Act lawsuit
In early 2017, a former Vanda employee filed a lawsuit alleging
violations of the False Claims Act. That action is captioned
United States ex rel. Gardner
v. Vanda Pharmaceuticals Inc., No. 17-464 (D.D.C.). After a
nearly two year investigation, the U.S. Department of Justice
announced in January 2019 that it
declined to intervene in the lawsuit, following which Vanda moved
to dismiss the lawsuit.
Corporate Contact:
AJ Jones II
Chief Corporate Affairs and Communications Officer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
Elizabeth Van Every
Head of Corporate Affairs
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
View original
content:http://www.prnewswire.com/news-releases/vanda-pharmaceuticals-wins-motion-to-dismiss-false-claims-act-lawsuit-301063123.html
SOURCE Vanda Pharmaceuticals Inc.